The company research program is powered by founder effects in Newfoundland and Labrador that bring the genetic drivers of disease into focus. Pairing those signals with deep clinical and family health histories supports causal evidence that links genes to disease.
Its discovery platform applies multi-omic analyses to powered cohorts across multiple indications. Pharmaceutical partners use the resulting insights to build evidence for new therapeutic approaches in areas of unmet medical need.
Sequence Bio is a commercial stage biotechnology company based in Newfoundland and Labrador. It states its purpose as discovering the genetic causes of disease within the province founder population to support new treatments, diagnostics, and preventions.
The team combines experience in human genetics, translational biology, and research ethics. Leadership includes founders and executives alongside board members drawn from the investor base in Atlantic Canada.
Sequence Bio operates a discovery platform that studies inherited causes of disease to identify drug targets and predictors of disease and treatment response. The platform combines genomic analysis with clinical data from consented cohorts in Newfoundland and Labrador.
Pharmaceutical and biotechnology partners apply the platform to target identification across indications that include dermatology. The company also runs enrollment programs such as its study of the genetic causes of inherited disease.
